Abbott, a global healthcare leader, has announced the launch of the International Cardio‑Renal Risk Assessment and Stratification (ICRAS) Tool, an innovative web‑based tool designed to help doctors across India to identify heart and kidney risks in people living with Type 2 Diabetes Mellitus (T2DM).
Developed with guidance from a distinguished expert panel, the ICRAS tool will help clinicians assess cardio‑renal risk early in people living with T2DM. By early risk stratification, the tool aims to improve health outcomes and reduce complications associated with T2DM.
India is often referred to as the “diabetes capital of the world,” with 101 million people currently living with diabetes. Heart and kidney conditions remain among the most common and serious complications of Type 2 diabetes. This makes early risk assessment especially important.
The ICRAS tool brings together important health indicators, including key medical test results and lifestyle factors, to generate separate risk scores for kidney disease, heart disease, and major cardiac events in people with Type 2 diabetes.
It also accounts for gender‑specific differences in risk, offering a clearer and more personalised summary of each diabetic patient’s risk of developing heart and kidney condition. Designed with privacy at its core, this web‑based tool does not capture any personal information about patients or doctors, ensuring all assessments remain fully secure.
Identifying high‑risk individuals early allows doctors to tailor care in meaningful ways. Timely, targeted interventions can slow or even prevent serious heart and kidney complications — helping people living with diabetes stay healthier for longer.
